Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma

Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma

Abstract Background Dasatinib (Sprycel) was developed as a tyrosine kinase inhibitor targeting Bcr-Abl and the family of Src kinases. Dasatinib is commonly used for the treatment of acute lymphoblastic and chronic myelogenous leukemia. Previous clinical studies in melanoma returned inconclusive resu...

Full description

Bibliographic Details
Main Authors: Josip Skoko, Jan Rožanc, Emilie M. Charles, Leonidas G. Alexopoulos, Markus Rehm
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Cell Biology
Subjects:
Melanoma
Dasatinib
Dacarbazine
Proliferation
Cell death
Online Access:http://link.springer.com/article/10.1186/s12860-018-0180-1

Internet

http://link.springer.com/article/10.1186/s12860-018-0180-1

Similar Items